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We have investigated c-erbB-2 protein expression in a large cohort of well-characterized colorectal tumours, and in a subset
of lymph node metastases. We have also evaluated a Val
655Ile single nucleotide polymorphism, which is associated with an
increased risk of breast cancer, in a subset of the colorectal cancer patients and in healthy control subjects.
Immunohistochemical studies revealed that while 81.8% of tumours expressed c-erbB-2, in the majority of cases equivalent
levels of c-erb-B2 were seen in adjacent normal mucosa. Colon tumours were signiﬁcantly more likely to express c-erbB-2 than
rectal tumours (P=0.015). Only 52.4% of the metastases displayed staining patterns concordant with their primary tumour,
indicating that determination of c-erbB-2 protein in colorectal tumours cannot predict the status of lymph node metastases.
PCR–RFLP analysis of the Val
655Ile single nucleotide polymorphism demonstrated that allele frequencies were identical
between colorectal cancer patients and a control group of Caucasian subjects (Ile=0.80 and Val=0.20 in each case), indicating
that it is not related to the risk of developing colorectal cancer in this population. Furthermore, there was no relationship
between c-erbB-2 protein expression and gene polymorphism (P=0.58). In terms of prognosis, no association was seen
between either c-erbB-2 protein expression or the presence of the Val allele and patient survival (P40.05 in each case),
suggesting that c-erbB-2 is not a prognostic marker in colorectal cancer.
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Colorectal cancer is the second most common malignancy in the
developed world (Parkin et al, 1993) and despite advances in treat-
ment strategies it remains a major cause of cancer mortality.
Currently, prognosis and choice of therapy are based solely on
the stage of the disease at presentation, which may not accurately
predict disease outcome. Thus, it is widely accepted that additional,
novel markers of disease progression need to be identiﬁed, in order
to individualize therapy accordingly (McLeod and Murray, 1999).
The c-erbB-2 (Her2, neu) proto-oncogene, located at chromosome
17q21, encodes a 185 kDa glycoprotein which is a member of the type
I kinase receptor family, and is involved in mediating a number of
normal cellular processes including proliferation (Hung and Lau,
1999). c-erbB-2 protein is frequently expressed at low levels in a vari-
ety of adult epithelial cells, however aberrant activation of c-erbB-2
due to ampliﬁcation and/or overexpression can contribute to unrest-
rained proliferation and tumour development or progression
(Klapper et al, 2000). Clinically, c-erbB-2 ampliﬁcation and/or over-
expression has been associated with poor prognosis in a number of
tumours, such as breast (Slamon et al, 1987; Winstanley et al,
1991), ovarian (Slamon et al, 1989; Berchuck et al, 1990) and gastric
(Amadori et al, 1997; Yonemura et al, 1998) neoplasms. However, the
utility of c-erbB-2 as a prognostic marker has not yet been established
in large cohorts of colorectal tumours.
Further study of c-erbB-2 in breast tumours recently demon-
strated that a Val
655Ile single nucleotide polymorphism (SNP) in
the transmembrane coding region of the c-erbB-2 gene (Papewalis
et al, 1991) was associated with an increased risk of breast cancer
(Xie et al, 2000). While it has not yet been determined if this poly-
morphism affects the ability of c-erbB-2 to transform cells, and/or
affects its tyrosine kinase activity, the relationship between the Val
allele and breast cancer suggests that this polymorphism may be
functionally important.
In addition to its roles as a prognostic marker and a risk factor,
c-erbB-2 is also the target of novel anti-cancer therapies, either in
the form of antibody-based therapy or tyrosine kinase inhibitors
(Mendelsohn and Baselga, 2000). Therefore, it is essential to accu-
rately assess the frequency of overexpression of c-erbB-2 in
colorectal tumours compared to normal tissue, and also to evaluate
c-erbB-2 expression in secondary lesions, in order to gauge the
likely efﬁcacy of anti-c-erbB-2 therapy in such tumours.
In this study, we have determined the frequency of overexpression
of c-erbB-2 protein in a large series of well-characterized colorectal
tumours, and in a subset of paired lymph node metastases. In addi-
tion, we have evaluated the Val
655Ile SNP in a subgroup of 151
colorectal cancer patients and 257 Caucasian control subjects to
determine if there is a relationship between the Val allele and risk
of colorectal cancer. Moreover, we have examined c-erbB-2 protein
overexpression and the presence of the Val allele with respect to clin-
icopathological information, including patient survival, to evaluate
the utility of c-erbB-2 as a prognostic marker in colorectal cancer.
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Patient information
Archived tumour samples were available from 249 patients who
underwent elective surgery for colorectal cancer at Grampian
University Hospitals NHS Trust (Scotland, UK). Tumours were
collected between 1994 and 1998 at the Department of Pathology,
University of Aberdeen, as part of the Aberdeen Colorectal Initia-
tive database. Samples were routinely ﬁxed in 10% neutral buffered
formalin for 24 h and embedded in parafﬁn-wax. An experienced
gastrointestinal pathologist conﬁrmed the diagnosis of adenocarci-
noma following review of all cases. Detailed clinicopathological
data (patient gender, site of primary tumour, degree of differentia-
tion, Dukes’ stage and patient age) is available for each sample.
Cases of peri-operative death were excluded from survival analysis
to avoid events that were not associated with disease. One hundred
and sixty-three of the 244 eligible patients were alive at the most
recent assessment (October 2000), with a median follow-up of 43
months (range 25–80 months).
A subset of 151 samples was used to determine the allele
frequencies of the Val
655Ile SNP in colorectal cancer. The genotype
and allele frequencies of these colorectal cancer samples were
compared with those of 257 healthy blood donor controls from
Aberdeen, UK, consisting of 140 male and 117 female volunteers,
median age 38 years (range, 17–66 years). All studies obtained
relevant approval from local ethical committees.
Immunohistochemistry
c-erbB-2 protein expression was analyzed in colorectal tumour
samples using immunohistochemistry. An avidin/biotin/horseradish
peroxidase development system was used as previously described
(McKay et al, 2000a,b) Formalin-ﬁxed wax embedded sections
(5 mm) were dewaxed, rehydrated and endogenous peroxidase
activity blocked using a 3% H2O2/methanol solution. Antigen
retrieval was achieved by microwaving sections for 20 min in
10 mM citrate buffer pH 6.0, and endogenous biotin activity was
blocked using a biotin blocking kit (Vector Laboratories Ltd, Peter-
borough, UK) to prevent non-speciﬁc background staining.
Following incubation with anti-c-erbB-2 monoclonal antibody
(NCL-CB11, 1 in 100 dilution; Novocastra, Newcastle upon Tyne,
UK), biotinylated rabbit anti-mouse immunoglobulin (Dako A/S
Ltd, Glostrup, Denmark) and streptavidin/biotin/ horseradish
peroxidase complex (Dako A/S Ltd), sites of bound antibody were
visualized using liquid DAB Plus (Dako A/S Ltd). Slides were then
counterstained with Mayer’s haematoxylin and analyzed using light
microscopy. Sections of an invasive breast adenocarcinoma were
used as positive controls, and slides were incubated with TBS in
place of primary antibody for negative controls.
Scoring systems
Sections were scored semi-quantitatively according to the following
USA FDA-approved scoring system (Jacobs et al, 1999): 0, no
immunostaining; 1+, complete membranous immunostaining of
510% of tumour cells; 2+, weak complete membranous staining
of 410% of tumour cells; 3+, strong complete membranous stain-
ing of 410% of tumour cells. Scores of 0 or 1+ indicate a negative
tumour, while scores of 2+ and 3+ were regarded as positive
expression of c-erbB-2. In addition, any normal colonic mucosa
present on the section was scored using the same system, and
the normal score subtracted from the tumour score. Using this
modiﬁed system, only cases with a value of 2 were considered c-
erbB-2 positive as previously described (Jacobs et al, 1999). Immu-
nostained tumour sections were analyzed independently by two
investigators without prior knowledge of clinicopathological data
and discrepancies were resolved by simultaneous re-evaluation.
DNA extraction
Genomic DNA was extracted from whole blood samples (5 ml)
using a sodium perchlorate-chloroform extraction method
(Nucleon II kit; Scotlab, Coatbridge, UK). Following extraction,
DNA was resuspended in 1 ml TE buffer (10 mM Tris-HCl,
1m M ethylenediamine tetraacetic acid, pH 8.0) and stored at
4
0C. Genomic DNA was also extracted from parafﬁn sections
containing formalin-ﬁxed normal colon tissue. Dewaxed and rehy-
drated material was placed in a microfuge tube, and digested with
0.5 mg ml
71 proteinase K for 4 h at 55ºC. Samples were then
heated to 95ºC for 3 min to inactivate the enzyme, and spun
brieﬂy to pellet any cell debris. The resulting supernatant was used
directly in PCR analysis.
PCR–RFLP analysis
Analysis was carried out essentially as previously described (Pape-
walis et al, 1991; Ameyaw et al, 2000; Xie et al, 2000). Each PCR
reaction (50 ml ﬁnal volume) consisted of 1 ml of sample DNA,
10 mM Tris-HCl, pH 8.3, 50 mM KCl (Perkin Elmer, Cheshire,
UK), 1.5 mM MgCl2 (Perkin Elmer), 200 mM each of dATP, dTTP,
dGTP and dCTP (Promega, Southampton, UK), 1 M betaine,
1.25U AmpliTaq Gold (Perkin Elmer) and 100 ng each of forward
and reverse primers (Gibco–BRL, Paisley, UK). Primers used in
the analysis of the c-erbB-2 Val
655Ile polymorphism in genomic
DNA were 5'-AGA GAG CCA GCC CTC TGA CGT CCA T
(forward primer HN-5), and 5'-TCC GTT TCC TGC AGC AGT
CTC CGC A (reverse primer HN-6, Papewalis et al, 1991). PCR
was carried out in a Hybaid Omnigene thermocycler (Hybaid,
Middlesex, UK), and consisted of an initial heating at 958C for
12 min to activate the enzyme, followed by 35 cycles of denatura-
tion at 948C for 30 s, annealing at 628C for 30 s and extension at
728C for 30 s, with a ﬁnal extension at 728C for 7 min. Genomic
DNA known to be homozygous for the Val allele was included
as a positive control, while DNA was omitted from negative
control samples.
PCR product (10 ml) was digested with 5 U BsmAI (New
England BioLabs, Hertfordshire, UK) at 558C for 2 h, and visua-
lized by electrophoresis on 2.5% agarose containing 0.5 mgm l
71
ethidium bromide. The 148 bp PCR product generated was cut
by BsmAI into fragments of 122 and 26 bp if the Ile allele was
present, whereas the product from the Val allele was cut to
produce fragments of 90, 32 and 26 bp (Figure 1). Genotypes were
assigned following visual identiﬁcation of unequivocal bands on
gels where complete digestion of the homozygous Val positive
control DNA had occurred.
Statistics
The relationship between c-erbB-2 protein expression in primary
colorectal tumours and lymph node metastases was evaluated using
the kappa test. Expression of c-erbB-2 protein, and the Val
655Ile
SNP, were assessed with respect to Dukes’ stage, degree of differen-
tiation, site of the primary tumour and patient gender using the
chi-squared test, while patient age was examined using the
Mann–Whitney U-test. The association between c-erbB-2 protein
expression and the Val
655Ile SNP was examined using the chi-
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150 bp
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Ile/Ile         Ile/Val        Val/Val
Figure 1 PCR–RFLP analysis of the c-erbB-2 Val
655Ile SNP.
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Kaplan–Meier survival plots and analyzed using the log rank test.
Signiﬁcance levels were set at P50.05, and all statistical analyzes
were carried out using SPSS for Windows 95 version 9.0 (SPSS
UK Ltd, Woking, Surrey, UK).
RESULTS
Immunohistochemistry
Primary colorectal tumours The expression of c-erbB-2 protein
was examined in 249 colorectal tumours. One primary tumour
gave inconsistent immunostaining results on repeated evaluations,
and was excluded from further analysis. The distribution of immu-
nostaining in primary colorectal tumours is detailed in Table 1,
which shows that although 81.5% of tumours expressed c-erbB-2,
only 8 out of 248 (3.2%) displayed strong immunoreactivity in
the membrane of tumour cells (Figure 2). Of the 204 samples
where normal colon mucosa could also be assessed, 174 had c-
erbB-2 scores of 2+ (165 cases) or 3+ (9 cases). Only 24 out of
204 (11.8%) samples displayed higher levels of c-erbB-2 in the
tumour compared to normal tissue, and none of these samples
reached a difference value of 52 (which was the deﬁnition of posi-
tive c-erbB-2 expression using the modiﬁed scoring system; Jacobs
et al, 1999).
Lymph node metastases c-erbB-2 expression was also assessed in
42 lymph node metastases from a subgroup of patients with Dukes’
stage C or D tumours. Twenty-one (50.0%) of the examined
metastases displayed positive c-erbB-2 immunoreactivity (Table
2). Of the 42 paired samples evaluated, 22 out of 42 (52.4%)
displayed equivalent c-erbB-2 expression in both the primary
tumour and the metastatic deposit. Of the remaining 20 pairs,
18 (42.9%) had higher c-erbB-2 expression in the primary tumour,
while two (4.8%) had elevated c-erbB-2 levels in the lymph node
lesion. Using the kappa test, which is a measure of agreement
between paired samples, only a poor level of concordance was
observed (k=0.048, P=0.634; Table 2).
c-erbB-2 protein and clinicopathological information
The expression of c-erbB-2 protein was evaluated with respect to
patient clinicopathological data, and the results detailed in Table
3. c-erbB-2 expression was associated with the site of the primary
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Table 1 Distribution of c-erbB-2 protein expression in colorectal cancer
(n=248)
Immunohistochemical score n %
0 negative 3 1.2
1+ 42 16.9
2+ positive 195 78.7
3+ 8 3.2 }
}
Figure 2 Representative examples of (A) strong membranous staining
of tumour cells, and (B) negative immunoreactivity for c-erbB-2, in primary
colorectal adenocarcinomas.
Table 2 c-erbB-2 protein expression in primary colorectal tumours and
corresponding lymph node matestases
Lymph node metastases
c-erbB-2
negative
c-erbB-2
positive
n (%) n (%) P
Colorectal tumour c-erbB-2 negative 3 (7.1) 2 (4.8)
c-erbB-2 positive 18 (42.9) 19 (45.2) 0.634
Table 3 c-erbB-2 protein expression and clinicopathological characteristics of colorectal cancer patients
c-erbB-2 negative c-erbB-2 positive
Characteristic Total n (%) n (%) P
Sex Male 134 23 (17.2) 111 (82.8)
Female 114 22 (19.3) 92 (80.7) 0.664
Site
a Proximal colon 90 11 (12.2) 79 (87.8)
Distal colon 99 16 (16.2) 83 (83.8)
Rectum 59 18 (30.5) 41 (69.5) 0.015
c
Differentiation Well 8 1 (12.5) 7 (87.5)
Moderate 204 35 (17.2) 169 (82.8)
Poor 36 9 (25.0) 27 (75.0) 0.486
Dukes’ stage
b A 32 6 (18.8) 26 (81.2)
B 122 20 (16.4) 102 (83.6)
C 90 18 (20.0) 72 (80.0)
D 4 1 (25.0) 3 (75.0) 0.898
Age Range 36—86 32—91
Mean 66 68
Median 67 69 0.405
aProximal colon tumours arose proximal to the splenic ﬂexure (i.e. caecum, ascending colon, transverse colon); distal colon tumours arose distal
to this point (i.e. the descending colon and sigmoid colon).
bColorectal cancers were classiﬁed as Dukes’ stage D when histologically conﬁrmed
liver metastases were present at the time of surgery.
cChi-squared test.
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British Journal of Cancer (2002) 86(4), 568–573 ã 2002 Cancer Research UKtumour, with the frequency of positive c-erbB-2 expression decreas-
ing from proximal colon to distal colon to rectum (P=0.015).
There was no correlation between c-erbB-2 protein expression
and patient gender, degree of differentiation, tumour stage, or
patient age (P40.05 in each case).
Val
655Ile SNP in colorectal cancer and control populations
The frequency of a polymorphic Val allele at position 655 of the c-
erbB-2 gene was assessed in a subset of 151 colorectal cancer
patients and in 257 Caucasian control subjects using PCR–RFLP
analysis. The genotype and allele frequencies are shown in Table
4. The genotype frequencies were not signiﬁcantly different from
the Hardy–Weinberg equilibrium in either population. These
two populations demonstrated an identical Val allele frequency
(0.20, P=0.999; Table 4).
There was no association between the Val allele and clinico-
pathological data (i.e. Dukes’ stage, differentiation grade, site,
gender or age), nor was there a relationship between this poly-
morphism and c-erbB-2 protein expression (P=0.582; Table 5).
c-erbB-2 and survival
The effects of c-erbB-2 protein expression, and the Val
655Ile SNP,
on patient survival were examined. No association was seen either
between protein expression, or the presence of the Val allele, and
patient outcome (P40.05 in each case; Figure 3).
DISCUSSION
The results of the present study indicate that: (1) although c-erbB-2
protein expression is frequently observed in colorectal tumours, it
is rarely at a higher level than adjacent normal tissue; (2) the
expression of c-erbB-2 protein in primary colorectal tumours does
not accurately reﬂect the c-erbB-2 status of lymph node metastases;
(3) a SNP at position 655 of the c-erbB-2 gene is not associated
with risk of colorectal cancer, nor does it inﬂuence protein expres-
sion; and (4) c-erbB-2 protein status and Val
655Ile SNP do not
inﬂuence patient survival in colorectal cancer patients.
The lack of differential expression between colorectal tumour
and normal tissue, and the lack of correlation between c-erbB-2
protein expression and tumour stage or grade, suggest that c-
erbB-2 does not play a major role in the development of colorectal
adenocarcinoma. There have been previous reports that have asso-
ciated c-erbB-2 protein expression with more aggressive colorectal
tumours. For example, colorectal tumours which subsequently
developed liver metastases more frequently expressed c-erbB-2
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Table 4 c-erbB-2 Val
655 Ile polymorphism in colorectal cancer controls
Genotype frequency Allele frequency
Population No of subjects Ile/Ile Ile/Val Val/Val Ile Val P
Colorectal 151 0.656 0.291 0.053 0.80 0.20
Cancer cases (0.76—0.84)
a (0.15—0.24)
Controls 257 0.654 0.292 0.054 0.80 0.20
(0.77—0.83) (0.17—0.23) 0.999
aNumbers in parentheses are 95% conﬁdence intervals.
Table 5 c-erbB-2 protein expression and Val
655 Ile polymorphism in
colorectal cancer
c-erbB-2 negative c-erbB-2 positive
Genotype n (%) n (%) P
Ile/Ile 12 (12.1) 87 (87.9)
Ile/Val 6 (14.0) 37 (86.0)
Val/Val 2 (25.0) 6 (75.0) 0.582
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Figure 3 Kaplan–Meier plots of the effects on colorectal cancer patient
outcome of (A)c - erbB-2 protein expression, and (B) the Val
655Ile SNP.
Neither of these factors were found to inﬂuence survival (P40.05 in each
case).
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(4), 568–573protein than those which did not metastasise in an 8-year period
(Yang et al, 1997), and in a further study cytoplasmic c-erbB-2
protein expression was associated with Dukes’ stage (Osako et al,
1998). However, Berney et al (1999) found that c-erbB-2 protein
was not associated with the risk of developing liver metastases.
The present study also found that c-erbB-2 protein expression
did not have predictive power for patient survival or other features
associated with an unfavourable outcome. There are several possi-
ble reasons for discrepancies between studies. The small sample size
of many studies of c-erbB-2 in colorectal cancer provides a source
of type II statistical error. The disparate scoring systems used to
classify c-erbB-2 overexpression (i.e. membranous and/or cytoplas-
mic immunostaining, per cent of positive tumour cells and/or
intensity of immunoreactivity) also make comparison between
studies very challenging. In addition, the source of the primary
antibody used, the immunohistochemical protocol and the size of
the sample set may all lead to inconsistencies between reports. This
highlights the need for a standardized system of c-erbB-2 classiﬁca-
tion as previously documented (van de Vijver, 2001).
In addition to its possible role in tumour development, c-erbB-2
overexpression is also a target of novel anti-cancer therapies (Sliw-
kowski et al, 1999; Mendelsohn and Baselga, 2000). While such
treatments are generally targeted against secondary lesions
(McLeod et al, 2000), markers of response are usually assessed in
primary tumour tissue, and it has been shown that metastatic
deposits often display a different biological composition to their
primary progenitor tumour cells (McKay et al, 2000b; McLeod et
al, 2000). Such differences may affect the expected efﬁcacy of treat-
ment.
We found that only approximately half of the examined paired
samples (52.4%) showed concordance between primary and
secondary tumours. While Sun et al (1994) found a signiﬁcant
association between c-erbB-2 protein expression in colorectal
adenocarcinomas and lymph node metastases, 30% of their samples
did not demonstrate equivalent immunostaining in primary and
secondary tumours. Taken together, these results indicate that the
c-erbB-2 protein status of colorectal tumours does not accurately
reﬂect the situation in metastatic lesions, and would be unable to
predict the likely efﬁcacy of anti-c-erbB-2 therapy in a large
proportion of secondary tumours.
The recently reported association between a c-erbB-2 SNP and
risk of breast cancer in a Chinese population (Xie et al, 2000),
led us to investigate possible links between this SNP and the devel-
opment of colorectal cancer. We found that the allele frequencies
for the Val allele were identical in a subset of our colorectal cancer
patients and a control group of healthy Caucasian blood donors.
This indicates that the presence of the polymorphic Val allele is
not associated with risk of colorectal cancer in Scottish Caucasians.
In addition, there was no relationship between the Val allele and c-
erbB-2 protein immunostaining in colorectal adenocarcinomas.
This does not infer a lack of functional signiﬁcance of the Val allele
in other normal or tumour tissues, especially breast malignancy.
Interestingly, the Val allele frequency (0.20) in this study is high-
er than both the control and case Val allele frequencies (0.11 and
0.15 respectively) seen in Chinese populations (Xie et al, 2000).
Further reports on the c-erbB-2 SNP have also indicated differences
in allele frequencies between ethnic groups (Ameyaw et al, 2000;
Baxter and Campbell, 2001), which is likely to inﬂuence the utility
of this SNP in global risk analysis.
To date, studies on the prognostic utility of c-erbB-2 protein
overexpression in colorectal tumours have reached conﬂicting
conclusions. Osako et al (1998) found that cytoplasmic c-erbB-2
protein was signiﬁcantly associated with poor prognosis in a group
of 146 colorectal tumours, and Kapitanovic et al (1997) found that
intensity of c-erbB-2 staining (membranous and/or cytoplasmic
staining) was independently related to survival in 155 colorectal
tumours. However, in agreement with our ﬁndings, Sun et al
(1995) showed that membranous c-erbB-2 expression in 293 color-
ectal tumours was not associated with prognosis, while
Chamberlain et al (1999), found no association between survival
and c-erbB-2 staining intensity (membranous and/or cytoplasmic
staining) in 96 colorectal tumours. As mentioned previously, these
discrepancies are likely due to procedural disparities. The present
study, which was carried out using highly reproducible automated
immunostaining on a large series of colorectal tumours with a
minimum of 25 months follow-up, has used recommended guide-
lines for assessing c-erbB-2 overexpression (Jacobs et al, 1999), to
allow straightforward comparisons with future studies.
There have been no previous reports on the inﬂuence of the
Val
655Ile SNP on the clinical outcome of colorectal cancer patients.
In the group of patients evaluated in this study, there was no asso-
ciation between the presence of the Val allele and patient survival.
In addition, we found no relationship between the c-erbB-2 SNP
and protein expression, indicating that evaluation of this SNP
would be of little beneﬁt in colorectal adenocarcinoma.
In conclusion, while c-erbB-2 appears to be highly important in
the development and progression of a number of epithelial malig-
nancies, the measurement of its protein expression and evaluation
of the Val
655Ile SNP is unlikely to be of clinical beneﬁt to patients
with colorectal adenocarcinoma.
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